Back to Search Start Over

J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy

Source :
PR Newswire. October 24, 2024
Publication Year :
2024

Abstract

SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ -- J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the Phase 1/2 clinical trial of its novel 4th-generation [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PR Newswire
Publication Type :
News
Accession number :
edsgcl.813363070